Shares of Hims & Hers Health dropped after JPMorgan lowered its price target from $35 to $33 following a mixed first-quarter report and a strategic shift from compounded to branded GLP-1 medications. Despite the cut, JPMorgan maintained an Overweight rating, while Canaccord raised its target to $32, viewing the quarter as a temporary setback. The company reported revenue growth but missed estimates, with margins compressing sharply. Management raised full-year revenue guidance and authorized a $250 million share buyback, signaling confidence beyond weight loss products. Investors should watch subscriber revenue trends and upcoming Q2 results to assess the success of the product transition and international expansion.
